- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Position paper on CDK4/6 inhibitors in early breast cancer ; volume:16 ; number:2 ; day:14 ; month:3 ; year:2023 ; pages:135-144 ; date:6.2023
Magazine of European Medical Oncology ; 16, Heft 2 (14.3.2023), 135-144, 6.2023
- Creator
-
Gnant, Michael
Singer, Christian
Rinnerthaler, Gabriel
Pfeiler, Georg
Egle, Daniel
Balic, Marija
Bartsch, Rupert
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-023-00878-1
- URN
-
urn:nbn:de:101:1-2023091012570111612748
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gnant, Michael
- Singer, Christian
- Rinnerthaler, Gabriel
- Pfeiler, Georg
- Egle, Daniel
- Balic, Marija
- Bartsch, Rupert
- SpringerLink (Online service)
Other Objects (12)
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
CDK4/6 inhibition in luminal breast cancer
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
CDK4/6 inhibition in luminal breast cancer
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
CDK4/6 inhibition in luminal breast cancer
Monitoring CDK4/6 inhibitor resistance in metastatic breast cancer patients using liquid biopsy markers
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer